// App-Quantinova.ai

: Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

Researchers

Presenter

  • Pedro C. Barata

Principal Investigators

  • Rachel Montgomery

  • Matthew Last

  • Liane Gillespie-Akar

  • Jonathan Nazari

  • Alexander Niyazov

Medical Centers

  • Adelphi Real World, Bollington, United Kingdom

  • Tulane University, New Orleans, LA

Locations

  • United Kingdom

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Prostate cancer

  • Fanconi anemia, complementation group A

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • MutL Homolog 1

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Nibrin

  • checkpoint kinase 2

  • Fanconi anaemia, complementation group A

  • Hormone receptor

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved